Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
EssilorLuxottica: Q1 2024 Revenue - Solid revenue trend in the first quarter
Q1 2024 RevenueSolid revenue trend in the first quarter Q1 revenue up 5.5% at constant exchange rates 1 All the regions growing, in both PS and DTC channelsAlso North America positive, on a softer paceStrong growth in EMEA, across all channels and categoriesProduct innovation and new brands as a key growth factor, driving price/mix upVarilux, Stellest and Ray-Ban Meta continuing to accelerate Charenton-le-Pont, France (April 18, 2024 - 6:00 pm)–...
Nasdaq GlobeNewswire
18/04/2024
Annual General Meeting 2024: Tecan shareholders endorse all motions proposed by…
Annual General Meeting 2024: Tecan shareholders endorse all motions proposed by the Board of DirectorsIncrease in the dividend from CHF 2.90 to CHF 3.00 per share Monica Manotas elected as additional independent member of the Board of DirectorsLukas Braunschweiler, Myra Eskes, Oliver Fetzer, Matthias Gillner, Karen Huebscher, Christa Kreuzburg and Daniel R. Marshak re-elected as members of the Board of DirectorsLukas Braunschweiler confirmed by shareholders as Chair of the...
Nasdaq GlobeNewswire
18/04/2024
Hemodialysis and Peritoneal Dialysis Market Worth $126.2 billion |…
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1279 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1279 Browse in-depth TOC on "Hemodialysis and Peritoneal Dialysis Market" 150 - Tables 65 - Figures 350 - Pages Hemodialysis and Peritoneal Dialysis Market Scope: Vascular complication associated with dialysis procedures and lack of well established reimbursement and coverage for...
PR Newswire
18/04/2024
Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00
Orphazyme A/S har afholdt ordinær generalforsamling den 18. april 2024 kl. 15:00 på selskabets adressehos Visionhouse, Lyskær 8A, 2730 Herlevmed følgende dagsorden: Bestyrelsens beretning om selskabets virksomhed i det forløbne regnskabsårFremlæggelse og godkendelse af årsrapport Anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapportBeslutning om meddelelse af decharge til bestyrelsen og direktionenPræsentation af vederlagsrapportenGodkendelse...
Nasdaq GlobeNewswire
18/04/2024
Pharming Group announces the placement of €100 million convertible bonds due…
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.Leiden, the Netherlands, 18th April, 2024:Pharming Group N.V. (" Pharming " or the " Company ") (Euronext Amsterdam: PHARM) announces today the placement of €100 million of senior unsecured convertible bonds due 2029 (the “ New Bonds ”) convertible into new and/or existing ordinary…
Nasdaq GlobeNewswire
18/04/2024
Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML…
Cognivia's solutions target critical areas that have historically posed significant challenges to drug development, such as the placebo response and medication adherence in clinical trials. Unlike any other, Cognivia is pioneering a quantitative understanding of patients as individuals and integrating these insights into the analysis of clinical trial data and/or optimization of patient engagement strategies. For instance, Placebell™ utilizes predictive algorithms to mitigate the negative impact…
PR Newswire
18/04/2024
Ultimovacs ASA – Annual General Meeting held on April 18, 2024
Oslo, April 18, 2023:Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved. The following board members were re-elected for a period of one year, and the Board of Directors will consist of the following persons:Jónas Einarsson, Chair of the BoardHenrik Schüssler, board member Kari Grønås, board member Ketil Fjerdingen, deputy board memberThe Nomination Committee will consist of the following persons until the Annual...
Nasdaq GlobeNewswire
18/04/2024
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3…
Poster presentation details are below and will be available on the Presentations and Publications page on the Calliditas' corporate website following the meeting. Poster presentation details are below and will be available on the Presentations and Publicationspageon the Calliditas' corporate website following the meeting. Poster Presentation Analyses: Poster Title : "Nefecon treatment provides kidney benefits for patients with IgAN that extend to those with low levels of UPCR: A...
PR Newswire
18/04/2024
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab…
Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, commented, “Tiziana is taking a leadership role in focusing on this subset of progressive MS where there are no effective treatments. One of the mechanisms thought to contribute to na-SPMS with PIRA is the activation of...
Nasdaq GlobeNewswire
18/04/2024
Mascara Market to Reach $14.1 billion, Globally, by 2032 at 8.3% CAGR: Allied…
Request The Sample PDF Of This Report: https://www.alliedmarketresearch.com/request-sample/A32210 Request The Sample PDF Of This Report:https://www.alliedmarketresearch.com/request-sample/A32210 Mascara is a cosmetic tool, designed to enhance the appearance of eyelashes by darkening, thickening, and extending them. Mascara comes in a tube with an applicator wand and is made up of a mixture of pigments, waxes, oils, and polymers. Together, these elements cover the lashes and add...
PR Newswire
18/04/2024
European Wellness Leads Pioneering Down Syndrome Research at Heidelberg…
EWBG, known for its groundbreaking work in stem cell therapy, has been at the forefront of this study, working closely with Heidelberg University. This collaboration demonstrates a shared commitment to transforming the care and treatment of Down Syndrome and associated diseases via cutting-edge scientific breakthroughs. EWBG, known for its groundbreaking work in stem cell therapy, has been at the forefront of this study, working closely with Heidelberg University. This collaboration...
PR Newswire
18/04/2024
Outrun Therapeutics launches with a $10m seed financing from M Ventures and MP…
Selective protein stabilisation by inhibiting specific E3 ligases will expand the disease indications that can be addressed with protein stabilisation and minimise side effects. There are ~700 E3 ligases representing the vast number of discrete cellular processes they control, providing potential targets for Outrun to develop effective precision medicines against. Selective protein stabilisation by inhibiting specific E3 ligases will expand the disease indications that can be addressed with...
PR Newswire
18/04/2024
Hansa Biopharma interim report January-March 2024
Clinical pipeline update Clinical pipeline update Events after closing period Financial summary Søren Tulstrup, President and CEO of Hansa Biopharma, comments: "I am very pleased with the strong commercial performance in the first quarter of 2024, the second consecutive quarter with solid product sales and a promising start to 2024. This strong sales performance is a continuation of the traction we saw at the end of last year where key large markets such as UK andGermanystarted...
PR Newswire
18/04/2024
Pharming Group announces the launch of an offering of approximately €100 million…
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming Group N.V. launches new convertible bond offering and simultaneously invites holders of its outstanding €125 million 3.00% convertible bonds due 2025 to offer their convertible bonds for purchase for cash Leiden, the Netherlands, 18th April, 2024:Pharming Group N.V. ("...
Nasdaq GlobeNewswire
18/04/2024
BioSenic S.A. : Transparency notifications received from François Rieger
PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, April 18, 2024, 7am CET –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received transparency notifications from François Rieger. Details of the notifications can be found below and the full versions of the...
Nasdaq GlobeNewswire
18/04/2024
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides…
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, April 18, 2024-Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company...
Nasdaq GlobeNewswire
18/04/2024
LG STRENGTHENS EUROPEAN PRESENCE WITH ITS KITCHEN SOLUTIONS SHOWCASE AT MDW 2024
Signature Kitchen Suite Built-in Oven with Advanced Cooking Technologies Signature Kitchen Suite Built-in Oven with Advanced Cooking Technologies Debuting at MDW 2024 and designed with European consumers in mind, the Signature Kitchen Suite 60-centimeter (24-inch) built-in oven offers a variety of cutting-edge features and AI technologies to elevate the culinary experience. Equipped with Gourmet AI™️, the oven can identify what the user is cooking and automatically select the appropriate...
PR Newswire
18/04/2024
Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by…
Key Takeaways from the Alport Syndrome Market Report Key Takeaways from the Alport Syndrome Market Report Discover which therapies are expected to grab the major Alport syndrome market share @Alport Syndrome Market Report Alport Syndrome Overview Alport syndrome denotes a range of hereditary, diverse conditions impacting the kidney's basement membranes, often with effects on the cochlea and eyes. It is a genetic condition resulting from mutations in the genes that code for...
PR Newswire
17/04/2024
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1…
Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations...
PR Newswire
17/04/2024
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and…
Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST PARIS and CAMBRIDGE, Mass., April17, 2024(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the fourth quarter and full year ended December...
Nasdaq GlobeNewswire
17/04/2024
Ipsen publishes its 2023 Universal Registration Document
Ipsen publishes its2023 Universal Registration DocumentPARIS, FRANCE, 17 April 2024 -Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty biopharmaceutical group, announces that its 2023 Universal Registration Document has been filed with the FrenchAutorité des Marchés Financierson 17 April 2024 and registered under the number D.24-0288.The document is available onipsen.comandamf-france.org. Copies will also be available at Ipsen's headquarters – 65 quai...
Nasdaq GlobeNewswire
17/04/2024
Derm-Biome Pharmaceuticals' topical therapy shows positive…
Derm-Biome Pharmaceuticals is a Vancouver-based biopharmaceutical company that has developed a topical anticancer treatment for patients with or at high risk of developing multiple AKs. In a recent UV-induced skin cancer trial, mice were exposed to UVB radiation over a period of 25 weeks. The prolonged exposure mimics chronic sun exposure over time and replicates the gradual progression from precancerous skin conditions to cutaneous squamous cell carcinoma (cSCC). Topical application of...
Nasdaq GlobeNewswire
17/04/2024
Patient Monitoring Devices Market Worth $71.1 billion | MarketsandMarkets™
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=678 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=678 Browse in-depth TOC on "Patient Monitoring Devices Market" 215 - Tables 55 - Figures 250 - Pages Patient Monitoring Devices Market Scope: Blood Glucose Monitoring systems segment to register a significant growth rate over the forecast period of 2024-2029. Based on the...
PR Newswire
17/04/2024
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing…
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3 2024COPENHAGEN, Denmark, April17, 2024(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces that the first patient in its EVX-01 Phase 2 trial in...
Nasdaq GlobeNewswire
17/04/2024
Altri Comunicati